These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12685397)

  • 1. [Quantitative assessment of protein replacement in therapeutic plasmapheresis].
    Kalinin NN; Movshev BE; Khester D; Petrova VI
    Ter Arkh; 2003; 75(2):65-8. PubMed ID: 12685397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Osmotic activity of plasma in plasmapheresis in patients with multiple myeloma].
    Movshev BE; Kalinin NN; Petrov MM; Petrova VI; Zhuravlev VS; Zakharova ES; Khoroshko ND
    Ter Arkh; 2001; 73(2):57-60. PubMed ID: 11338858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic plasmapheresis in immune complex diseases].
    Movshev BE; Kalinin NN; Petrova VI
    Ter Arkh; 1994; 66(7):70-3. PubMed ID: 7985137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Colloid osmotic pressure and the total protein level in assessing the safety of therapeutic plasmapheresis].
    Movshev BE; Semenova GM; Petrova VI; Kalinin NN
    Ter Arkh; 1991; 63(7):30-3. PubMed ID: 1788802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The monitoring of protein-volemic indices during plasmapheresis in patients with paraproteinemic hemoblastoses].
    Kalinin NN; Movshev BE; Petrov MM; Petrova VI; Droshneva VA; Varlamova SV; Khoroshko ND; Zhuravlev VS; Loginov SP
    Ter Arkh; 1996; 68(7):62-5. PubMed ID: 8928075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reestablishment of plasma proteins after plasmapheresis in patients with paraproteinemic hemoblastosis].
    Movshev BE; Kalinin NN; Petrov MM; Petrova VI
    Ter Arkh; 1999; 71(10):40-3. PubMed ID: 10612173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma proteins and other substances in membrane plasmapheresis. Relation to possibilities and limitations of this therapeutic method].
    Opatrný K; Opatrný K; Kováríková P; Cerhová M; Cepelák V; Rusnáková H; Sefrna F
    Vnitr Lek; 1989 Sep; 35(9):864-72. PubMed ID: 2815603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic plasmapheresis using a cell separator].
    Kalinin NN; Petrov MM; Petrova VJ
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):177-82. PubMed ID: 2475394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasma macroproteins in the evaluation of the effectiveness of therapeutic plasmapheresis in patients with rheumatoid arthritis].
    Movshev BE; Dubrovina NA; Petrova VI; Markova ML; Telitsina IA
    Revmatologiia (Mosk); 1989; (1):32-6. PubMed ID: 2664987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of plasmapheresis on the concentration of certain plasma proteins: a case identified by an inaccurate LDL-cholesterol estimation.
    Maguire OC; Mc Carthy D; Cunningham SK
    Ann Clin Biochem; 2008 Jul; 45(Pt 4):436-9. PubMed ID: 18583635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis.
    Yu X; Ma J; Tian J; Jiang S; Xu P; Han H; Wang L
    J Clin Rheumatol; 2007 Aug; 13(4):193-8. PubMed ID: 17762452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers.
    Tran-Mi B; Storch H; Seidel K; Schulzki T; Haubelt H; Anders C; Nagel D; Siegler KE; Vogt A; Seiler D; Hellstern P
    Vox Sang; 2004 Apr; 86(3):189-97. PubMed ID: 15078254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of replacement fluids used for therapeutic plasma exchange on plasma viscosity and plasma oncotic pressure.
    Tek I; Arslan O; Arat M; Ayyildiz E; Tol M; Oral M; Ilhan O
    Transfus Apher Sci; 2004 Oct; 31(2):89-93. PubMed ID: 15501412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis.
    Kimura K; Tsuda H; Kwangseok Y; Tamura N; Kanai Y; Kobayashi S
    Ther Apher Dial; 2005 Feb; 9(1):64-8. PubMed ID: 15828909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced blood-to-tissue albumin movement after plasmapheresis.
    Stahl AM; Gillen CM; Takamata A; Nadel ER; Mack GW
    Shock; 2003 May; 19(5):440-7. PubMed ID: 12744487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The blood protein system in therapeutic plasmapheresis in patients with rheumatoid arthritis].
    Movshev BE; Markova ML; Kalinin NN; Petrova VI; Dubrovina NA
    Revmatologiia (Mosk); 1988; (1):9-13. PubMed ID: 3291070
    [No Abstract]   [Full Text] [Related]  

  • 17. Albumin catabolism in hypoproteinaemic states studies with 131-I-albumin.
    Freeman T; Gordon AH
    Bibl Haematol; 1965; 23():1108-15. PubMed ID: 5894593
    [No Abstract]   [Full Text] [Related]  

  • 18. Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch.
    Auwerda JJ; Leebeek FW; Wilson JH; van Diggelen OP; Lam KH; Sonneveld P
    Transfusion; 2006 Oct; 46(10):1705-11. PubMed ID: 17002626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
    Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
    Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
    Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
    Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.